Send to

Choose Destination
Curr Cancer Drug Targets. 2018;18(2):188-201. doi: 10.2174/1568009617666170330123841.

Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.

Author information

Division of Gastroenterology, Faculty of Medicne, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305- 8575, Japan.
Center for Stem Cell Research, Center for Infectious Diseases and Cancer Research, Graduate Institute of Medicine, Kaohsiung Medical University, 80708 Kaohsiung, Taiwan.


Advanced liver cancers and biliary cancers represent diseases with dismal prognosis because of frequent local invasion and metastasis. Effective therapeutic agents for these cancers have not been established. Oncolytic viruses (OVs) constitute a novel class of promising, selective anticancer agents and recent studies have elucidated their unique features. Moreover, clinical trials are demonstrating promising results. Numerous OVs are being tested in preclinical models of hepatocellular carcinoma (HCC). The lead agent Pexa-Vec (pexastimogene devacirepvec, JX-594), a recombinant Wyeth strain vaccinia virus, has demonstrated preliminary evidence of safety and efficacy for HCC in clinical trials. Few other OVs have entered clinical testing. Relatively few preclinical studies and clinical trials exist for biliary cancers. In this review, we introduce various approaches using OVs to treat the intractable hepatobiliary cancers.


Gene therapy; adenovirus; bile duct cancer; gallbladder cancer; oncolytic virus; virotherapy

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center